<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03476122</url>
  </required_header>
  <id_info>
    <org_study_id>CMx-CTC-CRC-001</org_study_id>
    <nct_id>NCT03476122</nct_id>
  </id_info>
  <brief_title>Clinical Application of an Automated Liquid Biopsy Platform for Early Detection of Colorectal Cancer</brief_title>
  <official_title>Application of an Automated Liquid Biopsy System in the Detection of Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CellMaxLife</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CellMaxLife</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer (CRC) is among the most preventable cancers when precancerous lesions are&#xD;
      detected at an early stage. Current screening methods for CRC require bowel prep or&#xD;
      stool-based testing that are inconvenient, resulting in low compliance. Stool based tests&#xD;
      have limited sensitivity for the detection of precancerous lesions.&#xD;
&#xD;
      The CMx platform has been showed to be able to the detection of Circulating Tumor Cells&#xD;
      (CTCs) in high sensitivity and specificity. In published studies, circulating Tumor Cells&#xD;
      (CTCs) are captured and quantified in advanced-stages of colorectal cancer. In order to&#xD;
      detect early and pre-cancer circulating tumor cells, we have developed an Automated Liquid&#xD;
      Biopsy Platform that improves the detection of CTCs in early cancer stages. Therefore, this&#xD;
      study goals are: 1) to establish a standard detection process utilizing the Automated Liquid&#xD;
      Biopsy Platform. 2) Parallel comparison of laboratory manual operation and Automated Liquid&#xD;
      Biopsy Platform. 3) Verify the feasibility of use of an Automated Liquid Biopsy Platform in&#xD;
      the clinical setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Selection of patients:&#xD;
&#xD;
           A. The disease group includes 300 patients diagnosed with stages 0-4 colorectal cancer&#xD;
           not previously treated.&#xD;
&#xD;
           B. The control group includes 450 control subjects who will undergo a colonoscopy&#xD;
           procedure.&#xD;
&#xD;
        2. Study stages&#xD;
&#xD;
           Stage I: The laboratory manually analyzes circulating tumor cells to establish a&#xD;
           standard detection process for Automated Liquid Biopsy System&#xD;
&#xD;
           Stage II: Comparison analysis between manual and Automated Liquid Biopsy Platform,&#xD;
           establishing the procedural and analytical models for the Automated Liquid Biopsy&#xD;
           Platform&#xD;
&#xD;
           Stage III: Verification of the feasibility of use of an Automated Liquid Biopsy Platform&#xD;
           in the clinical setting.&#xD;
&#xD;
        3. Methods&#xD;
&#xD;
      I. CTC isolation Peripheral blood drawn from subjects will be processed using the CMx&#xD;
      platform or the automated liquid biopsy system for detection and capture.&#xD;
&#xD;
      II. Characterization of isolated CTC using Immunofluorescence Staining&#xD;
&#xD;
      III. CRC-related gene expression The serum and circulating tumor cells isolated from the&#xD;
      blood will be used to extract RNA, and then be analyzed with the expression of different&#xD;
      genes by real-time quantitative polymerase chain reaction (real-time PCR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">March 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of circulating tumor cells</measure>
    <time_frame>Prior to treatment or colonoscopy</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Colo-rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Disease Group</arm_group_label>
    <description>The disease group is diagnosed with colorectal cancer 0-4 and has not been treated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>The control group will receive Colonoscopy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Colorectal cancer patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. The disease group is diagnosed with colorectal cancer 0-4 and has not been treated.&#xD;
&#xD;
          -  2. The control group will receive Colonoscopy&#xD;
&#xD;
          -  3. Above 20 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Refuse to sign the informed consent form&#xD;
&#xD;
          -  2. Received surgery within one month&#xD;
&#xD;
          -  3. Previous cancer history&#xD;
&#xD;
          -  4. Autoimmune diseases&#xD;
&#xD;
          -  5. Chronic inflammatory diseases&#xD;
&#xD;
          -  6. Acute inflammatory or infectious diseases in three months&#xD;
&#xD;
          -  7. Myelodysplastic syndromes and myeloproliferative disorder&#xD;
&#xD;
          -  8. Other diseases decided by PI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Sy Tsai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yun-Tsui Chang</last_name>
    <phone>+886-2-26558455</phone>
    <phone_ext>404</phone_ext>
    <email>joy@cellmaxlife.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wen-Jan Chiang</last_name>
    <phone>+886-2-26558455</phone>
    <phone_ext>404</phone_ext>
    <email>wenjan@cellmaxlife.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Sy Tsai</last_name>
      <phone>+886-3-381200</phone>
      <phone_ext>2101</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2018</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>CRC</keyword>
  <keyword>Circulating tumor cells</keyword>
  <keyword>CTCs</keyword>
  <keyword>Early detection</keyword>
  <keyword>Automated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

